Drug repurposing for rare disease treatment leads to reduced risk

Director of the Drug Discovery Platform of Parc Científic Barcelona, Jordi Quintana and his team secured funding to investigate a rare disease, amyloidosis. They set out to study a subset of the disease called familial amyloid polyneuropathy. Because of the rare nature of the disease and the limited patient base, traditional drug discovery and development techniques were not an option.